Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalFRA:IC7 78 EV-to-EBITDA is 19.57 as of Aug. 18, 2026, which is 12% below its 10-year median of 22.13. GuruFocus rates FRA:IC7 with a GF Score™ of 78/100 and a GF Value™ of €103.53 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 513 Medical Devices & Instruments companies, ICU Medical ranks worse than 64.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ICU Medical's enterprise value is €4,785 Mil.
ICU Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €244 Mil. Therefore, ICU Medical's EV-to-EBITDA for today is 19.57.
The historical rank and industry rank for ICU Medical's EV-to-EBITDA or its related term are showing as below:
FRA:IC7'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.83 Med: 22.13 Max: 75.06
Current: 19.42
During the past 13 years, the highest EV-to-EBITDA of ICU Medical was 75.06. The lowest was 11.83. And the median was 22.13.
FRA:IC7's EV-to-EBITDA is ranked worse than 64.52% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.95
vs FRA:IC7: 19.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ICU Medical's PE Ratio (TTM) for today is calculated as:
ICU Medical's share price for today is €157.00.
ICU Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.032.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ICU Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IC7 vs NVST, MMSI, MMED: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ICU Medical's EV-to-EBITDA falls into.
ICU Medical's current Enterprise Value is €4,785 Mil.
ICU Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €244 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical (FRA:IC7) has a EV-to-EBITDA of 19.57 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ICU Medical. This is 12% below median its historical median of 22.13. Over the past decade, ICU Medical's EV-to-EBITDA has ranged from 11.83 to 75.06. According to the industry distribution chart, ICU Medical ranks #331 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 64.5%.
Is ICU Medical's EV-to-EBITDA too high?
ICU Medical's current EV-to-EBITDA of 19.57 is 12% below median its 10-year median of 22.13. Over the past 10 years, this metric has ranged from a low of 11.83 to a high of 75.06. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.95. ICU Medical's value of 19.57 is 30.9% above this industry median. Based on the distribution chart, ICU Medical ranks #331 out of 513 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ICU Medical has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's EV-to-EBITDA compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #331 out of 513 companies for EV-to-EBITDA. This places ICU Medical in the lower half of its industry. The industry median EV-to-EBITDA is 14.95. ICU Medical's value of 19.57 is 30.9% above this benchmark. Historically, ICU Medical's own EV-to-EBITDA has ranged from 11.83 to 75.06 over the past decade. While the company's 10-year median is 22.13 vs. the industry median of 14.95, ICU Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.95, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current EV-to-EBITDA of 19.57 is 30.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ICU Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current EV-to-EBITDA is 19.57, which is 12% below median its own 10-year median of 22.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (FRA:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €103.53, compared to a current price of €157.00 — trading 51.6% above its estimated fair value. The current EV-to-EBITDA is 19.57, which is 12% below median its 10-year median of 22.13 and 30.9% above the Medical Devices & Instruments industry median of 14.95. ICU Medical's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ICU Medical (FRA:IC7), the current EV-to-EBITDA is 19.57 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (FRA:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €157.00 is trading 51.6% above its estimated GF Value™ of €103.53.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for FRA:IC7:
EV-to-EBITDA: 19.57 (12% below median its 10-year median of 22.13)
GF Value™: €103.53 vs. price of €157.00 (51.6% above fair value)
Industry Position: 30.9% above the Medical Devices & Instruments median (#331 of 513)
No single metric tells the full story. See the FRA:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
78GF Score
Get the complete analysis for FRA:IC7
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IC7 has been successfully added to your 
